Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma
BioFactors · 2024-11 · 50 (6) · 1208-1219
DOI: 10.1002/biof.2078 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, online erschienen am 17.05.2024. Verfasst von Cristina Aguzzi und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Camerino, Camerino, MC, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Cannabinoids, Xenograft Model Antitumor Assays. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Multiple myeloma (MM) is a blood cancer caused by uncontrolled growth of clonal plasmacells. Bone disease is responsible for the severe complications of MM and is caused by myeloma cells infiltrating the bone marrow and inducing osteoclast activation. To date, no treatment for MM is truly curative since patients relapse and become refractory to all drug classes. Cannabinoids are already used as palliative in cancer patients. Furthermore, their proper anticancer effect was demonstrated in many cancer models in vitro, in vivo, and in clinical trials. Anyway, few information was reported on the effect of cannabinoids on MM and no data has been provided on minor phytocannabinoids such as cannabigerol (CBG), cannabichromene (CBC), cannabinol (CBN), and cannabidivarin (CBDV). Scientific literature also reported cannabinoids beneficial effect against bone disease. Here, we examined the cytotoxic activity of CBG, CBC, CBN, and CBDV in vitro in MM cell lines, their effect in modulating MM cells invasion toward bone cells and the bone resorption. Subsequently, according to the in vitro results, we selected CBN for in vivo study in a MM xenograft mice model. Results showed that the phytocannabinoids inhibited MM cell growth and induced necrotic cell death. Moreover, the phytocannabinoids reduced the invasion of MM cells toward osteoblast cells and bone resorption in vitro. Lastly, CBN reduced in vivo tumor mass. Together, our results suggest that CBG, CBC, CBN, and CBDV can be promising anticancer agents for MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Camerino, Camerino, MC, Italy.
- Integrative Therapy Discovery Lab, University of Camerino, Camerino, MC, Italy.
- School of Bioscience and Veterinary Medicine, University of Camerino, Camerino, MC, Italy.
- Entourage Biosciences Inc., Vancouver, Canada.
ORCID-Profile: Massimo Nabissi
Zitieren
APA
Aguzzi, C., Zeppa, L., Morelli, M. B., Marinelli, O., Giangrossi, M., Amantini, C., Santoni, G., Sazzad, H., & Nabissi, M. (2024). Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma. BioFactors, 50(6), 1208-1219. https://doi.org/10.1002/biof.2078
Vancouver
Aguzzi C, Zeppa L, Morelli MB, Marinelli O, Giangrossi M, Amantini C, et al. Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma. BioFactors. 2024;50(6):1208-1219. doi:10.1002/biof.2078
BibTeX
@article{Aguzzi2024,
author = {Aguzzi, Cristina and Zeppa, Laura and Morelli, Maria Beatrice and Marinelli, Oliviero and Giangrossi, Martina and Amantini, Consuelo and Santoni, Giorgio and Sazzad, Hossain and Nabissi, Massimo},
title = {Anticancer effect of minor phytocannabinoids in preclinical models of multiple myeloma},
journal = {BioFactors},
year = {2024},
volume = {50},
number = {6},
pages = {1208--1219},
doi = {10.1002/biof.2078}
}
EUVIMED